Patent SG-11201900027X-A (SG)
Title: Anti-o2 antibodies and uses thereof
Inventor: WANG QUN
IPC: C12P21/08
Filed: 2017-08-04
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111101111011101 HRH 110 1 001111010M 0111110111111011110111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/027124 Al 08 February 2018 (08.02.2018) WIP0 I PCT (51) International Patent Classification: Med SA, Mirasole 1, CH-6500 Bellinzona (CH). BEL- A 61K 39/02 (2006.01) A61K 39/40 (2006.01) TRAMELLO, Martina; Humabs BioMed SA, Mirasole A61K 39/108 (2006.01) A61K 31/715 (2006.01) 1, CH-6500 Bellinzona (CH). KAPLAN, Gilad; Medlm- A61K 39/395 (2006.01) Cl 2P 21/08 (2006.01) mune, Llc, One Medlmmune Way, Gaithersburg, MD (21) International Application Number: 20878 (US). DEMARCO, Anna; Humabs BioMed SA, Mirasole 1, Bellinzona CH-6500 (CH). PCT/US2017/045480 (22) International Filing Date: (74) Agent: MARTIN, Cynthia, Lan et al.; Medlmmune, LLC, 04 August 2017 (04.08.2017) One Medimmune Way, Gaithersburg, MD 20878 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/371,402 05 August 2016 (05.08.2016) US DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicants: MEDIMMUNE, LLC [US/US]; One Medlm- KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, mune Way, Gaithersburg, MD 20878 (US). HUMABS, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, BIOMED, SA [CH/CH]; Mirasole 1, CH (CH). -6500 Bellinzona OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (72) Inventors: WANG, Qun; Medlmmune, Llc, One Medlm- mune Way, Gaithersburg, MD 20878 (US). STOVER, (84) Designated States (unless otherwise indicated, for every Charles, K.; Medlmmune, Llc, One Medlmmune Way, kind of regional protection available): ARIPO (BW, GH, = Gaithersburg, MD 20878 (US). PENNINI, Meghan; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Medlmmune, Llc, One Medlmmune Way, Gaithersburg, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = _ MD 20878 (US). XIAO, Xiaodong; Medlmmune, Llc, One TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — Medlmmune Way, Gaithersburg, MD 20878 (US). CORTI, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Davide; Humabs BioMed SA, Mirasole 1, CH-6500 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Bellinzona (CH). CAMERONI, Elisabetta; Humabs Bio- = (54) Title: ANTI-02 ANTIBODIES AND USES THEREOF = = Fla - IA = = 0-serotype D-Galactan determining = antigen al cts H D-Galactan I , , KPDI ,, .., ., 4 = = = = = CD LPS-0 _ c - Es antigen co (73 7 c) - L - as r, co • To- 57) ) c n r Wz//4 V — = — Il .4 core , core A 0-antigen 1 2 3 4 5 7 12 ei N 01 02 serotype 1-1 IN (57) : The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically 0 \" bind ---- from a lethal to Klebsiellapneumoniae 02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) GO , 1 or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneu- moniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject. ei C [Continued on next page] WO 2018/027124 Al MIDEDIMOMMIDIIMERIONMOIDEEDHOMEMOVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) he Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))